
Sign up to save your podcasts
Or


The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data to help researchers and drug developers understand what works, what doesn’t, and why. On Wednesday, January 24th, at 10:00 a.m. PT/1:00 p.m. ET, drug trial participant Bill Sasse, who was a participant in Eli Lilly’s clinical trial of experimental monoclonal antibody drug solanezumab, joins Being Patient Live Talks to discuss his experience with the drug trial. In March of 2023, solanezumab ultimately failed to hit its benchmarks in slowing cognitive decline and the trial was discontinued.
By Being Patient4.6
99 ratings
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data to help researchers and drug developers understand what works, what doesn’t, and why. On Wednesday, January 24th, at 10:00 a.m. PT/1:00 p.m. ET, drug trial participant Bill Sasse, who was a participant in Eli Lilly’s clinical trial of experimental monoclonal antibody drug solanezumab, joins Being Patient Live Talks to discuss his experience with the drug trial. In March of 2023, solanezumab ultimately failed to hit its benchmarks in slowing cognitive decline and the trial was discontinued.

7,208 Listeners

1,320 Listeners

12,738 Listeners

704 Listeners

2,038 Listeners

1,678 Listeners

4,910 Listeners

3,531 Listeners

9,258 Listeners

8,747 Listeners

142 Listeners

8,188 Listeners

2,064 Listeners

20,420 Listeners

16 Listeners